首页> 外国专利> ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOF

ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOF

机译:Etoricoxib溶剂化物及其制备方法

摘要

The disclosure relates to etoricoxib solvates and a preparation method thereof. A solvent is a hydrogen bond donor solvent with a polarity value π* ranging from 60 to 100 or a hydrogen bond acceptor solvent with a polarity value π* ranging from 92 to 100. Solvents with a polarity value π* within the above range all can form corresponding etoricoxib solvates with etoricoxib. The etoricoxib solvate can be prepared by cooling crystallization or suspension crystallization. A 1,2-propanediol solvate of etoricoxib and a dimethyl sulfoxide (DMSO) solvate of etoricoxib provided in the present disclosure have high thermal stability, unique crystal form, large size, concentrated distribution, and prominent flowability and is safe, pharmaceutically acceptable, and not easy to agglomerate. Compared with etoricoxib, the etoricoxib solvates exhibit significantly improved solubility. Moreover, preparation of the solvates requires low consumption in time, energy, and solvent, and has high efficiency, with a molar yield higher than 90%.
机译:本公开涉及Etoricoxib溶剂化物及其制备方法。溶剂是氢键供体溶剂,其极性值π*范围为60至100或氢键受体溶剂,其极性值π*范围为92-100.在上述范围内具有极性值π*的溶剂形成相应的Etoricoxib溶剂化物与eToricoxib。肉毒酶溶剂化物可以通过冷却结晶或悬浮结晶来制备。本公开中提供的eToricoxib的1,2-丙二醇溶剂化物和肉毒蛋白酶的二甲基亚甲醚(DMSO)溶剂化物具有高热稳定性,独特的晶体形式,大尺寸,浓缩分布和突出的流动性,并且是安全的,药学上可接受的,并且不容易凝聚。与肠道毒素相比,Etoricoxib溶剂化物具有显着提高的溶解度。此外,溶剂化物的制备需要在时间,能量和溶剂的较低,并且具有高效率,摩尔产率高于90%。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号